

Amendments

In the Claims:

Please cancel claims 127-134.

Please add the following new claims.

Sub D1
183. (new) An isolated polypeptide comprising an amino acid sequence at least 90% identical to Ser (69) - Ser (208) of SEQ ID NO:2.

Sub E1
184. (new) The isolated polypeptide of claim 183, having a Met residue at the N-terminus of said amino acid sequence.

C1
185. (new) The isolated polypeptide of claim 183, wherein said polypeptide is part of a fusion protein.

186. (new) The isolated polypeptide of claim 183, which is produced in a recombinant cell.

187. (new) The isolated polypeptide of claim 186, wherein said recombinant cell is bacterial.

Cont E1
188. (new) The isolated polypeptide of claim 183, together with a pharmaceutically acceptable carrier or excipient.

Sub D2
189. (new) An isolated polypeptide comprising an amino acid sequence at least 95% identical to Ser (69) - Ser (208) of SEQ ID NO:2.

Cont E1
190. (new) The isolated polypeptide of claim 189, having a Met residue at the N-terminus of said amino acid sequence.

191. (new) The isolated polypeptide of claim 189, wherein said polypeptide is part of a fusion protein.

192. (new) The isolated polypeptide of claim 189, which is produced in a recombinant cell.

Cont C
193. (new) The isolated polypeptide of claim 192, wherein said recombinant cell is bacterial.

194. (new) The isolated polypeptide of claim 189, together with a pharmaceutically acceptable carrier or excipient.

Sub D3
195. (new) An isolated polypeptide comprising an amino acid sequence at least 97% identical to Ser (69) - Ser (208) of SEQ ID NO:2.

196. (new) The isolated polypeptide of claim 195, having a Met residue at the N-terminus of said amino acid sequence.

Cattell
197. (new) The isolated polypeptide of claim 195, wherein said polypeptide is part of a fusion protein.

198. (new) The isolated polypeptide of claim 195, which is produced in a recombinant cell.

C 199. (new) The isolated polypeptide of claim 198, wherein said recombinant cell is bacterial.

200. (new) The isolated polypeptide of claim 195, together with a pharmaceutically acceptable carrier or excipient.
